🔴 Lantern Pharma is trading 9.33% down today after September 16's advance; catalyst unclear

Lantern Pharma is trading at $1.75, down 9.33%, with no confirmed company-specific announcement explaining the September 17 decline.

• The company announced a September 23 webinar covering its Open-Medicine AI subsidiary and development roadmap; the positive update does not directly explain today’s drop.
• Broader biotechnology sentiment is positive, while the stock follows September 16’s 13.53% advance, suggesting possible profit-taking.